- Home
- EBON vs OSRH Comparison
EBON vs OSRH Comparison
Compare EBON & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBON | OSRH |
|---|---|---|
| Founded | 2010 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 18.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EBON | OSRH |
|---|---|---|
| Price | $2.45 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 574.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.39 |
| 52 Week High | $5.90 | $4.33 |
Technical Indicators
Market Signals| Indicator | EBON | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 38.08 |
| Support Level | $2.30 | N/A |
| Resistance Level | $3.76 | $0.76 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 20.85 | 25.29 |
Price Performance
Historical ComparisonAbout EBON Ebang International Holdings Inc.
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
About OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.